New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
06:17 EDTICPTIntercept initiated with a Neutral at Goldman
Goldman Sachs started shares of Intercept with a Neutral rating saying it's difficult to value the company's obeticholic acid for the treatment of nonalcoholic steatohepatitis without the FLINT trial data, which is due out later this year. Goldman put a $265 price target on the stock.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
07:33 EDTICPTIntercept management to meet with Deutsche Bank
Subscribe for More Information
April 23, 2015
05:44 EDTICPTIntercept FLINT trial data shows OCA treatment increases fibrosis resolution
Subscribe for More Information
April 22, 2015
07:07 EDTICPTEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use